Trials / Terminated
TerminatedNCT00419081
Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens
A Phase IIb, Multicenter, Open-Label, Nonrandomized, Repeat-Dose Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (planned)
- Sponsor
- BioCryst Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Forodesine Hydrochloride is effective in treating patients with relapsed/refractory precursor T-Lymphoblastic Leukemia/Lymphoma who have failed two or more prior treatment regimens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Forodesine Hydrochloride Sterile Solution, 5 mg/mL | |
| DRUG | Forodesine Hydrochloride Capsules (100 mg) |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2007-03-01
- Completion
- 2007-03-01
- First posted
- 2007-01-08
- Last updated
- 2012-01-23
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00419081. Inclusion in this directory is not an endorsement.